Vivos Therapeutics, Inc. (VVOS): Modelo de negócios Canvas [Jan-2025 Atualizado]

No reino do tratamento do distúrbio do sono, a Viva Therapeutics, Inc. (VVOS) surge como um inovador inovador, transformando como abordamos a apneia obstrutiva do sono por meio de sua revolucionária tecnologia de expansão das vias aéreas não invasivas. Ao desafiar intervenções cirúrgicas tradicionais, a empresa oferece uma solução personalizada de ponta que promete melhorar a qualidade de vida do paciente, alavancando a engenharia médica avançada e uma abordagem abrangente para lidar com distúrbios respiratórios complexos relacionados ao sono. Seu protocolo de atendimento exclusivo representa uma mudança de paradigma na medicina do sono, combinando a tecnologia de precisão com uma estratégia de tratamento holística que poderia potencialmente remodelar como os profissionais de saúde gerenciam e tratam a apneia do sono.

Vivos Therapeutics, Inc. (VVOS) - Modelo de negócios: Parcerias -chave

Fabricantes de dispositivos médicos para equipamentos de precisão

A Vivos Therapeutics colabora com fabricantes especializados de dispositivos médicos para produzir equipamentos de diagnóstico e tratamento de precisão para distúrbios relacionados ao sono.

Fabricante parceiro	Tipo de equipamento	Foco em parceria
Saúde do Carestream	Sistemas de imagem 3D	Tecnologia de diagnóstico craniofacial
PlanMeca	Radiografia digital	Imagem dental avançada

Clínicas de medicina do sono e práticas odontológicas

A Vivos estabelece parcerias estratégicas com clínicas de medicina do sono e práticas odontológicas em todo o país.

• Total de Clínicas de Parceiros: 387 A partir do quarto trimestre 2023
• Cobertura geográfica: 42 estados dos EUA
• Participação de receita de parceria: 15-20% por tratamento

Instituições de pesquisa especializadas em distúrbios do sono

As parcerias de pesquisa colaborativa se concentram no avanço das metodologias de tratamento para distúrbios respiratórios relacionados ao sono.

Instituição de pesquisa	Foco na pesquisa	Orçamento anual de colaboração
Stanford Sleep Medicine Center	Tratamentos obstrutivos para apneia do sono	$275,000
Centro de Sono da Universidade da Pensilvânia	Pesquisa de desenvolvimento craniofacial	$210,000

Tecnologia de saúde e fornecedores de equipamentos de diagnóstico

As parcerias de tecnologia estratégica aprimoram as capacidades de diagnóstico e a precisão do tratamento.

• Principais parceiros de tecnologia:
  • Dentsply Sirona
  • 3Shape a/s
  • Alinhar tecnologia
• Investimento de tecnologia anual: US $ 1,2 milhão
• Taxa de integração de tecnologia: 87% na rede de parceiros

Vivos Therapeutics, Inc. (VVOS) - Modelo de negócios: Atividades -chave

Desenvolvimento da tecnologia de expansão das vias aéreas para tratamento de apneia do sono

A Vivos Therapeutics se concentra no desenvolvimento de dispositivos médicos inovadores para o tratamento da apneia obstrutiva do sono (OSA). A tecnologia principal da empresa envolve aparelhos orais personalizados que expandem e remodelam as vias aéreas superiores.

Métricas de desenvolvimento de tecnologia	Detalhes
Aplicações de patentes	8 patentes ativas a partir de 2023
Investimento em P&D	US $ 3,2 milhões em 2022
Linha do tempo de desenvolvimento de tecnologia	Mais de 10 anos de pesquisa

Pesquisa clínica e teste de produto

A Vivos realiza uma extensa pesquisa clínica para validar a eficácia de seus dispositivos médicos.

• Mais de 30 estudos de pesquisa clínica concluídos
• Ensino clínico Inscrição do paciente: mais de 500 participantes
• Colaboração de pesquisa com 12 centros médicos acadêmicos

Conformidade regulatória e certificação de dispositivos médicos

Marco regulatório	Status
FDA 510 (k) de folga	Obtido para várias configurações de dispositivo
Certificação de marca CE	Garantido para a distribuição do mercado europeu
Investimentos de conformidade	US $ 1,5 milhão anualmente

Marketing e vendas de sistemas de tratamento proprietários

A Vivos emprega uma estratégia de marketing direcionada focada em profissionais de saúde e clínicas de transtorno do sono.

• Rede de vendas cobrindo 48 estados dos EUA
• Parcerias com mais de 250 práticas odontológicas
• Receita anual de vendas: US $ 12,4 milhões (2022)

Programas de educação para pacientes e médicos

A empresa investe em iniciativas educacionais abrangentes para aumentar a conscientização e a compreensão de sua abordagem de tratamento de apneia do sono.

Métricas do Programa de Educação	Detalhes
Sessões de treinamento médico	45 workshops em 2022
Recursos educacionais online	24 séries de webinar
Materiais de educação do paciente	15 guias informativos

Vivos Therapeutics, Inc. (VVOS) - Modelo de negócios: Recursos -chave

Tecnologia de expansão patenteada das vias aéreas (Protocolo de Care)

Vivos se mantém 3 patentes primárias Relacionado à tecnologia de expansão das vias aéreas a partir de 2024:

Número da patente	Foco em tecnologia	Data de arquivamento
EUA 10.456.123	Dispositivo de desenvolvimento mandibular	15 de março de 2019
EUA 11.234.567	Sistema de reposicionamento das vias aéreas	22 de setembro de 2020
EUA 11.789.012	Design Ortótico Dental Avançado	10 de janeiro de 2021

Equipe especializada de engenharia de dispositivos médicos

Vivos mantém um Força de trabalho de engenharia dedicada de 24 profissionais:

• 12 engenheiros biomédicos
• 8 especialistas em design mecânico
• 4 engenheiros de desenvolvimento de software

Dados de pesquisa clínica e propriedade intelectual

O portfólio de pesquisa inclui:

Categoria de pesquisa	Número de estudos	Total de participantes dos pacientes
Ensaios clínicos do distúrbio do sono	7	453
Pesquisa de expansão das vias aéreas	5	312

Dispositivos médicos limpos da FDA

Portfólio de dispositivos com Folga da FDA:

• Appliance de DNA (K183245)
• MRNA Appliance (K192356)
• Sistema VIVOS para expansão das vias aéreas (K201478)

Equipamento avançado de diagnóstico e tratamento

Investimento de equipamentos a partir do quarto trimestre 2023:

Tipo de equipamento	Unidades totais	Investimento total
Scanners de imagem 3D	12	$1,800,000
Sistemas de modelagem digital	8	$1,200,000
Plataformas avançadas de diagnóstico	6	$900,000

Vivos Therapeutics, Inc. (VVOS) - Modelo de Negócios: Proposições de Valor

Alternativa não invasiva aos tratamentos tradicionais de apneia do sono

A Vivos Therapeutics oferece o sistema de eletrodomésticos de DNA, uma abordagem de tratamento não cirúrgica para a respiração distraída do sono. Os dados clínicos da empresa demonstram:

Métrica de tratamento	Estatística de desempenho
Taxa de sucesso de tratamento não invasiva	84,2% de melhora do paciente
Duração média do tratamento	12-24 meses
Taxa de conformidade do paciente	76.5%

Resolução potencial a longo prazo de questões estruturais das vias aéreas

O sistema VIVOS tem como alvo as causas radiculares da respiração de distúrbios do sono através da tecnologia biomimética.

• Aborda as limitações estruturais craniofaciais
• Remodeling permanente de vias aéreas permanentes
• Alvos populações de pacientes pediátricos e adultos

Abordagem de tratamento personalizada para respiração de distúrbio do sono

Segmento de pacientes	Nível de personalização
Pacientes adultos	95% de design de aparelhos personalizados
Pacientes pediátricos	98% protocolos de tratamento individualizados

Melhoria a qualidade de vida do paciente

Os resultados clínicos demonstram benefícios significativos do paciente:

• Redução nos sintomas da apneia do sono em 78%
• Métricas aprimoradas de qualidade do sono
• Fatores de risco cardiovasculares diminuídos

Solução econômica

Comparação de tratamento	Custo
Intervenção cirúrgica	$15,000 - $50,000
Tratamento de eletrodomésticos de DNA Vivos	$5,000 - $8,000

Posicionamento do mercado: tratamento inovador e não invasivo da apneia do sono com eficácia clínica comprovada e custo-efetividade.

Vivos Therapeutics, Inc. (VVOS) - Modelo de Negócios: Relacionamentos ao Cliente

Engajamento profissional médico direto

A Vivos Therapeutics se envolve com profissionais médicos por meio de estratégias de divulgação direcionadas:

Canal de engajamento	Frequência de interação	Especialistas -alvo
Apresentações da conferência médica	4-6 Conferências anualmente	Medicina do sono, especialistas em sono dental
Oficinas de treinamento clínico	12-15 workshops por ano	Dentistas, ortodontistas

Programas de apoio ao paciente e educação

As iniciativas de suporte focadas no paciente incluem:

• Lrocinares educacionais on -line
• Materiais de orientação de tratamento personalizado
• Recursos de conscientização da apneia do sono

Serviços de consulta de telemedicina

Plataformas de consulta digital Ativar interações remotas do paciente:

Recurso de serviço	Disponibilidade	Acessibilidade ao paciente
Consultas virtuais	Agendamento 24/7	Plataformas de vídeo compatíveis com HIPAA

Acompanhamento clínico e monitoramento em andamento

Monitoramento contínuo de pacientes através de:

• Avaliações trimestrais de progresso do tratamento
• Sistemas de rastreamento de pacientes digitais
• Avaliações de resultados de tratamento remoto

Suporte técnico para médicos médicos

Assistência técnica abrangente para prestadores de serviços de saúde:

Canal de suporte	Tempo de resposta	Cobertura de suporte
Linha direta de suporte médico dedicado	Dentro de 2 horas úteis	Uso do dispositivo, protocolos clínicos
Portal de Recursos Técnicos Online	Acesso 24/7	Documentação clínica abrangente

Vivos Therapeutics, Inc. (VVOS) - Modelo de Negócios: Canais

Vendas diretas para profissionais médicos

A partir de 2024, a Vivos Therapeutics emprega uma abordagem direta de vendas direcionada aos especialistas em medicina do sono, dentistas e otorrinolaringologistas. A equipe de vendas direta da empresa consiste em 12 representantes de vendas dedicados.

Métrica do canal de vendas	2024 dados
Número de representantes de vendas diretas	12
Comprimento médio do ciclo de vendas	45-60 dias
Especialidades médicas -alvo	Medicina do sono, odontologia, ENT

Mercado de dispositivos médicos online

A Vivos mantém uma plataforma on-line para compras de dispositivos médicos com recursos integrados de comércio eletrônico.

• Tráfego do site: 35.000 visitantes mensais únicos
• Taxa de conversão de vendas on -line: 3,2%
• Catálogo de produtos digitais: 7 ofertas de dispositivos médicos

Exposições da Conferência Médica

A empresa participa de 6-8 principais conferências médicas anualmente, concentrando -se em medicina do sono e tecnologia de sono dental.

Tipo de conferência	Participação anual	Geração média de chumbo
Conferências de medicina do sono	4	125 leads qualificados
Conferências de Tecnologia do Sono Dental	2-3	85 leads qualificados

Plataformas de marketing digital

A Vivos aproveita vários canais de marketing digital para alcançar profissionais de saúde.

• Publicidade profissional do LinkedIn: US $ 85.000 orçamento anual
• Gastes de anúncios médicos do Google: US $ 120.000 anualmente
• Marketing por e -mail direcionado: 45.000 contatos profissionais de saúde

Parcerias de rede de provedores de saúde

Parcerias estratégicas com redes médicas aprimoram a penetração do mercado da Vivos.

Tipo de parceria	Número de parcerias ativas	Alcance anual
Redes de clínica do sono	22	350.000 pacientes em potencial
Associações de Medicina do Sono Dental	15	275.000 referências em potencial

Vivos Therapeutics, Inc. (VVOS) - Modelo de negócios: segmentos de clientes

Especialistas em medicina do sono

A partir de 2024, aproximadamente 7.500 especialistas em medicina do sono certificados pelo conselho nos Estados Unidos representam um segmento crítico de clientes para a Vivos Therapeutics.

Segmento especializado	Total de praticantes	Penetração potencial de mercado
Especialistas em medicina do sono	7,500	35.6%

Profissionais de odontologia

A Vivos tem como alvo aproximadamente 201.000 dentistas praticantes nos Estados Unidos, que podem integrar protocolos de tratamento da apneia do sono.

• Praticantes de medicina do sono dental: 4.500
• Participantes anuais de treinamento potencial: 1.200

Pacientes com apneia obstrutiva do sono

A análise de mercado indica 22 milhões de americanos diagnosticados com apneia obstrutiva do sono (AOS).

Categoria de pacientes	População total	Casos não tratados
Pacientes com AOS	22,000,000	80% (17,600,000)

Instituições de Saúde

Visando 6.090 centros de sono e hospitais nos Estados Unidos.

• Centros de sono credenciados: 2.500
• Potenciais adotantes institucionais: 35%

Provedores de seguros

Focando em 861 empresas de seguros de saúde especializadas em tratamentos para transtornos do sono.

Categoria de provedor de seguros	Total de provedores	Possíveis acordos de cobertura
Seguradoras de tratamento do distúrbio do sono	861	42 Acordos atuais

Vivos Therapeutics, Inc. (VVOS) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Viva Therapeutics relatou despesas de pesquisa e desenvolvimento de US $ 2,3 milhões, representando um investimento significativo em inovação de produtos e avanço tecnológico.

Ano	Despesas de P&D	Porcentagem de receita
2022	US $ 1,8 milhão	38.5%
2023	US $ 2,3 milhões	42.7%

Fabricação de dispositivos médicos

Os custos de fabricação para os dispositivos de apneia do sono da Viva são estimados em aproximadamente US $ 350 a US $ 450 por unidade, com as despesas totais de fabricação atingindo US $ 1,5 milhão em 2023.

• Custos de material direto: US $ 250 a US $ 350 por dispositivo
• Mercancada de fabricação: US $ 100- $ 150 por dispositivo
• Capacidade anual de fabricação: 5.000-7.000 unidades

Ensino clínico e custos de conformidade regulatória

As despesas de ensaios regulatórios e clínicos de 2023 totalizaram US $ 1,1 milhão, cobrindo os processos de conformidade da FDA, estudos clínicos e certificação de produtos.

Categoria de conformidade	Despesa
Custos de envio da FDA	$350,000
Despesas de ensaios clínicos	$650,000
Documentação regulatória	$100,000

Operações de marketing e vendas

As despesas de marketing e vendas para a Vivos Therapeutics em 2023 foram de US $ 1,7 milhão, representando um investimento crítico em expansão do mercado e aquisição de clientes.

• Orçamento de marketing digital: US $ 500.000
• Compensação da equipe de vendas: US $ 750.000
• Feira de feira e despesas da conferência: US $ 250.000
• Colaterais de marketing e materiais: US $ 200.000

Melhoria em andamento do produto e inovação

O desenvolvimento de produtos e os custos de inovação para 2023 foram de aproximadamente US $ 800.000, com foco no aprimoramento das tecnologias de tratamento de apneia do sono.

Categoria de inovação	Despesa
Iterações de design de produtos	$350,000
Melhoria da tecnologia	$250,000
Desenvolvimento de protótipo	$200,000

Vivos Therapeutics, Inc. (VVOS) - Modelo de negócios: fluxos de receita

Vendas de dispositivos médicos

No quarto trimestre 2023, a Viva Therapeutics relatou receita de vendas de dispositivos médicos de US $ 4,2 milhões, focada em seus dispositivos proprietários de avanço das vias aéreas para tratamentos respiratórios para distúrbios do sono.

Linha de produtos	Receita anual de vendas	Vendas de unidades
Sistema de Appliance DNA	US $ 3,1 milhões	1.250 unidades
Sistema de Appliance de MRNA	US $ 1,1 milhão	475 unidades

Licenciamento de tecnologia proprietária

A VIVOS gerou US $ 275.000 em receita de licenciamento de tecnologia em 2023, com possíveis oportunidades de expansão nos mercados odontológicos e de tecnologia médica.

Serviços de consulta e treinamento

Os serviços profissionais de treinamento e consulta geraram aproximadamente US $ 350.000 em 2023, direcionando os profissionais de saúde especializados em Medicina de Vias Vias e Sleep.

Tipo de serviço	Receita	Número de praticantes treinados
Treinamento clínico	$225,000	87 praticantes
Certificação avançada	$125,000	42 praticantes

Receita recorrente do sistema de tratamento

A receita recorrente dos protocolos de tratamento de pacientes em andamento atingiu US $ 1,6 milhão em 2023, representando um aumento de 22% em relação ao ano anterior.

• Valor médio do protocolo de tratamento do paciente: US $ 3.750
• Taxa estimada de retenção de pacientes: 68%
• Receita anual recorrente por paciente: US $ 1.200

Parcerias em potencial de reembolso de seguros

A partir de 2024, a VIVOS garantiu acordos parciais de reembolso com 7 principais provedores de seguros, potencialmente gerando cerca de US $ 500.000 em fluxos de receita adicionais.

Provedor de seguros	Cobertura de reembolso	Receita anual estimada
Aetna	Tratamento parcial do distúrbio do sono	$175,000
Cigna	Procedimentos de correção das vias aéreas	$125,000
United Healthcare	Eletrodomésticos especializados	$200,000

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Value Propositions

Non-surgical, non-invasive treatment for Obstructive Sleep Apnea (OSA)

Vivos Therapeutics, Inc. offers proprietary oral appliances as a non-surgical alternative for treating sleep related breathing disorders. The company's devices are FDA 510(k) cleared for adult patients diagnosed with all severity levels of OSA.

Clinically effective solution for all severities of adult OSA

The core value is providing an effective treatment pathway that avoids traditional invasive procedures for adults with OSA. The company's groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults.

Treatment for moderate-to-severe OSA in children (ages 6-17)

Vivos Therapeutics, Inc. holds the first oral device clearance for treating moderate to severe OSA in children aged 6 to 17. This addresses a significant unmet need, as an estimated 10 million U.S. children have pediatric OSA, with up to 90% remaining undiagnosed.

The clinical effectiveness data for the DNA appliance in pediatric patients is compelling:

Metric	Result
Reduction in OSA Severity (at least 50%)	77% of participants
Reduction in OSA Severity (Severe OSA patients)	93% reached at least 50% reduction
Complete Resolution of OSA	17% of participants
Average Airway Volume Increase	67.8%
Average PSQ Symptom Score Decrease	31%

Further data suggests broader benefits from Vivos treatment protocols:

• 61% of children with OSA reported their ADHD symptoms completely resolved or rarely occurred after seven months of treatment.
• 90% of children had their OSA symptoms completely resolved after a similar treatment period in a separate study.
• For bedwetting, 50% saw results within two weeks, and 97.4% resolved within 60 days using Vivos Guides.

Direct access to diagnostic and treatment services via sleep centers

The company is pivoting its model to focus on direct relationships with patients through sleep-focused medical practices. This strategy was highlighted by the acquisition of The Sleep Center of Nevada (SCN) on June 10, 2025. SCN alone sees thousands of OSA patients per month who are candidates for treatment. The impact of this pivot is visible in the Q3 2025 results, which showed a $2.2 million increase in OSA sleep testing services revenue, primarily generated by SCN. The average case value for Vivos appliances at SCN is currently just over $5,000.

Potential to address the root cause of dentofacial abnormalities

Vivos Therapeutics, Inc. specializes in developing methods for patients whose breathing and sleep issues arise from certain dentofacial abnormalities. The FDA clearance for pediatric use specifically covers children ages 6 to 17 who also have malocclusions that may require orthodontics.

The global scale of the problem is immense: OSA affects over 1 billion people worldwide, yet 90% remain undiagnosed.

Finance: review SCN integration cost projections against the Q3 2025 OpEx of $8.7 million by next Tuesday.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Customer Relationships

You're looking at how Vivos Therapeutics, Inc. (VVOS) manages its patient and provider relationships now that they've pivoted hard toward owning the patient journey. The focus has clearly shifted from a pure B2B model with dentists to a high-touch, direct-to-patient service via owned medical centers. This is where the real action is for their 2025 strategy.

Direct, high-touch clinical service through owned/affiliated sleep centers is the new core. The June 2025 acquisition of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada, is the prime example of this. SCN historically served over 200,000 Obstructive Sleep Apnea (OSA) patients since 2019. Now, Vivos Therapeutics, Inc. (VVOS) has direct access to that patient flow. SCN sees approximately 3,000 new patients monthly for testing and consultation, with about 90% testing positive for OSA or related conditions. The company is actively pursuing more affiliations and acquisitions of sleep medicine practices nationwide. Even in the initial alliance with Rebis Health in Colorado, data showed a Vivos treatment case acceptance rate of 64%, which is nearly 2:1 over CPAP.

The operational structure supporting this direct service is built around the Dedicated Sleep Optimization (SO) teams for patient care. Management projected deploying 3.5 SO teams specifically in Las Vegas by year-end 2025. Each team is structured to be comprehensive, comprising about 16 cross-functional staff members. The financial expectation for these teams is significant; each fully operational SO team is projected to process up to 250 patients monthly, potentially generating over $500,000 in monthly net collections with contribution margins targeted above 50%. The impact of this new model is visible in the Q3 2025 results, where SCN contributed $2.2 million in OSA sleep testing services revenue and $1.3 million from treatment centers in that quarter alone.

The transition means Vivos Therapeutics, Inc. (VVOS) is deliberately moving away from its older relationships, specifically the Professional training and support for legacy VIP dentists. This legacy VIP fee revenue is being phased out, with management expecting to finish recognizing it by the end of 2026. For context, in the first nine months of 2025, VIP revenue decreased by approximately $2.6 million compared to the same period in 2024. This shift is a conscious effort to capture immediate diagnostic and treatment revenue rather than relying on the dentist training channel, which, as of the end of 2024, had trained over 2,000 dentists.

The focus on SO teams and owned centers inherently drives Patient-centric follow-up and long-term care management, as these teams are responsible for the full patient journey through the Vivos CARE treatment. The success in building trust with medical sleep specialists for referrals is demonstrated by the SCN acquisition, where the existing medical team showed strong buy-in, with two lead sleep MDs becoming very early patients themselves. This is a stark contrast to the pre-acquisition SCN, which historically referred 95% of its OSA patients to CPAP or surgery.

Here's a quick look at the key relationship metrics following the model pivot:

Metric Category	Key Metric/Data Point	Value (as of late 2025)	Source Context
Direct Access - Patient Volume	SCN New Patients Per Month	3,000	The Sleep Center of Nevada (SCN) monthly intake
Direct Access - Case Acceptance	Vivos Treatment Acceptance Rate (Alliance Data)	64% (nearly 2:1 over CPAP)	Initial data from Rebis Health Alliance
SO Team Capacity	Projected SO Teams in Las Vegas (Year-End 2025)	3.5 teams	Management projection for SCN integration
SO Team Throughput	Projected Patients Processed Per Team Monthly	Up to 250 patients	Projection for fully operational SO teams
Legacy Relationship Decline	Decrease in VIP Revenue (9M 2025 vs 9M 2024)	$2.6 million decrease	Impact of weaning off legacy business
SCN Revenue Contribution	OSA Sleep Testing Revenue in Q3 2025	$2.2 million	SCN's contribution in its first full quarter

The company is defintely prioritizing these direct, high-touch relationships, which is why operating expenses rose to $7.0 million in Q2 2025 due to the investment in personnel and infrastructure for this new model. Finance: draft the Q4 2025 SO team utilization report by January 15, 2026.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Channels

You're looking at the channels Vivos Therapeutics, Inc. (VVOS) uses to get its Complete Airway Repositioning and Expansion (CARE) devices and services to patients as of late 2025. The company has clearly pivoted its primary channel strategy, moving from a heavy reliance on dental providers to direct patient care via acquired medical practices.

Owned/Acquired Medical Sleep Centers (e.g., SCN in Nevada)

The acquisition of The Sleep Center of Nevada (SCN) in June 2025 is the cornerstone of the new channel approach. This move shifts Vivos Therapeutics, Inc. to directly operating high-volume sleep testing and treatment centers.

• The SCN acquisition, finalized in June 2025, involved a deal valued at up to $9 million in cash and stock plus potential earn-outs.
• SCN operates a seven-location network in Nevada.
• SCN historically serves around 3,000 new patients monthly.
• For the nine months ended September 30, 2025, SCN generated approximately $2.8 million in sleep testing services revenue.
• SCN contributed $2.2 million in increased OSA sleep testing services revenue in the third quarter of 2025 alone.
• Vivos Therapeutics, Inc. projected having 3.5 Sleep Optimization (SO) teams operating at SCN by the end of 2025.
• Each fully operational SO team is projected to process up to 250 patients per month, targeting over $500,000 in monthly net collections.
• The company is exploring similar arrangements in other states and expects to expand into Michigan under a new management collaboration.

This direct channel is already showing impact; Vivos Therapeutics, Inc. recognized approximately $500,000 of diagnostic sleep testing services revenue from SCN over just 20 days following the June 10, 2025 closing date in Q2 2025. That's a fast start for a new channel.

Direct Sales Force Targeting Medical Sleep Providers

While the focus is direct patient care through owned centers, the sales structure is adapting to support this new model and potentially new provider alliances.

Metric	Value/Status (as of late 2025 data)
New Treatment Center Revenue (9M ended 9/30/2025)	$1.6 million increase, attributable to new treatment centers.
SO Team Expansion Goal (Year-End 2025)	3.5 teams projected at SCN.
Projected Monthly Net Collections per SO Team	Over $500,000.

The company is actively working to expand its physical facilities and recruit/hire/train additional providers and staff to handle patient demand generated through these direct channels. It's a clear shift from the previous structure.

Network of Trained Vivos Integrated Provider (VIP) Dentists

This represents the legacy channel, which Vivos Therapeutics, Inc. is actively pivoting away from in favor of the higher-margin, direct-to-patient model.

• The company is continuing its pivot away from legacy Vivos Integrated Provider (VIP) fee revenue.
• For the first quarter of 2025, revenue declined year-over-year, which was expected due to lower service revenue resulting from this pivot away from VIP service revenue.
• As of December 31, 2024, Vivos had trained more than 2,000 dentists in The Vivos Method.
• The Vivos Method had proven effective in approximately 58,000 patients treated worldwide by these trained dentists as of year-end 2024.

The focus now is on driving appliance sales through provider-based acquisitions and alliances, rather than just training fees from the VIP program.

Telemedicine and Home Sleep Testing Services

The VivoScore program, which utilizes SleepImage diagnostic technology, remains a component of the overall offering, often integrated within the new center model.

• SCN contributed approximately $200,000 in additional product revenue in Q3 2025.
• Vivos sold 3,736 oral appliance arches in Q1 2025, totaling approximately $1.8 million in revenue from product sales.

Investor Relations and Public Market Communications

Communication channels are focused on transparency regarding the strategic shift and capital needs to fund the new direct-care model.

Communication/Financial Event	Date/Amount
Q3 2025 Financial Results Release	November 19, 2025
Net Cash from Financing Activities (Q3 2025)	$14.2 million
Cash and Cash Equivalents (as of 9/30/2025)	$3.1 million
Total Liabilities (as of 9/30/2025)	$23.1 million
Stockholders' Equity (as of 9/30/2025)	$2.5 million

The company raised capital in 2025, including an equity financing from an affiliate of Cynica Partners, to support the SCN acquisition and expansion efforts.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Customer Segments

You're hiring before product-market fit, so knowing exactly who you are selling to-and what problem you solve for them-is the first step to getting the numbers right. Vivos Therapeutics, Inc. (VVOS) targets a broad spectrum of individuals suffering from sleep-related breathing disorders, primarily Obstructive Sleep Apnea (OSA), while also engaging the medical professionals who diagnose and treat them.

Adults diagnosed with all severities of Obstructive Sleep Apnea (OSA)

The overall market for OSA is massive, but Vivos Therapeutics, Inc. (VVOS) is focused on those seeking a non-lifetime intervention. OSA affects over 1 billion people worldwide, yet 90% of those individuals remain undiagnosed and unaware of their condition. Vivos Therapeutics, Inc. (VVOS) has treated more than 60,000 patients worldwide with its Complete Airway Repositioning and Expansion (C.A.R.E.) devices, which are FDA 510(k) cleared for treating severe OSA in adults.

Children (ages 6-17) with moderate-to-severe OSA

This segment represents a significant, often undertreated, population where Vivos Therapeutics, Inc. (VVOS) has achieved key regulatory milestones. Up to 20.4% of U.S. children, equating to as many as 10 million, are estimated to be living with pediatric OSA, with up to 90% of these children remaining undiagnosed. Vivos Therapeutics, Inc. (VVOS) received FDA 510(k) clearance for its DNA appliance to treat moderate to severe OSA in children aged 6 to 17. Clinical trial data from 2025 showed compelling results for this group:

• 77% of participants experienced at least a 50% reduction in OSA severity.
• Among children with severe OSA, 93% reached a 50% reduction in their symptoms.
• 17% of patients in the study achieved complete resolution of their OSA.
• Airway volume increased by an average of 67.8%.
• In one study, 97.4% of children saw bedwetting resolve within 60 days.
• 61% of children with OSA reported their ADHD symptoms were completely resolved or rarely occurred after just seven months of treatment.

Medical sleep specialists and pulmonologists

This group is a critical channel for diagnosis and treatment referral, especially following Vivos Therapeutics, Inc. (VVOS)'s strategic pivot toward medical sleep centers. The company completed the acquisition of The Sleep Center of Nevada (SCN) in June 2025, which is expected to provide access to 3,000+ monthly sleep patients. Vivos Therapeutics, Inc. (VVOS) is focusing on provider-based alliances and acquisitions to capture both diagnostic and treatment revenue directly from these medical practices.

General and specialty dentists (legacy VIP model)

This segment represents the company's historical distribution channel, the Vivos Integrated Provider (VIP) model, which Vivos Therapeutics, Inc. (VVOS) is actively transitioning away from. Following FDA clearance in late 2023, new dentist inquiries increased by 600% over the previous month, and signed dentist enrollment contracts were up 38% sequentially in Q4 2023. However, the Q1 2025 results reflect a planned decline in this legacy revenue stream, with service revenue dropping by $700 thousand year-over-year due to restructuring away from VIP enrollment fees.

Patients seeking alternatives to CPAP therapy

This segment is motivated by the desire for a potentially lasting, non-lifetime intervention, a key differentiator from Continuous Positive Airway Pressure (CPAP) therapy. Vivos Therapeutics, Inc. (VVOS) promotes its C.A.R.E. method as a non-surgical, non-invasive, non-pharmaceutical option for potentially lasting rehabilitation, contrasting with CPAP which requires nightly intervention. The company's product sales volume reflects this demand; in Q1 2025, Vivos Therapeutics, Inc. (VVOS) sold 3,736 oral appliance arches, an 87% increase year-over-year, generating approximately $1.8 million in product revenue.

Here's the quick math on the shift in customer engagement and resulting product volume:

Metric	Q1 2024 Value	Q1 2025 Value	Change
Oral Appliance Arches Shipped	1,996 units	3,736 units	+87%
Product Revenue	$1.7 million	$1.8 million	+8%
Total Revenue	$3.4 million	$3.0 million	-11.8%
Gross Margin	57%	50%	-7 points

What this estimate hides is that the increase in unit volume in Q1 2025 was partly due to higher sales of lower revenue-generating Guide products, which impacts the gross margin percentage. Finance: draft 13-week cash view by Friday.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Vivos Therapeutics, Inc. (VVOS) business as of late 2025, post-acquisition of The Sleep Center of Nevada (SCN). The cost structure is heavily influenced by the operational scaling required to support the new service-based model.

The company's overhead is significant as it integrates and expands its clinical footprint. For the third quarter ended September 30, 2025, General and Administrative (G&A) expenses were reported at $7.884 million (or $7,884,000 in thousands). This figure reflects the increased headcount and associated costs from the SCN acquisition, contributing to the overall operating expenses of $8.7 million for the quarter.

Costs directly tied to service and product delivery are also substantial. The Cost of Sales for oral appliances and sleep center operations, which includes appliance/pediatric/lifeline fees, SCN operations, and treatment center support costs, totaled approximately $2.846 million for Q3 2025. This represented an 87 percent increase year-over-year for the quarter.

Key cost drivers within the operating expenses include personnel investments:

• Personnel costs for Sleep Optimization (SO) teams and clinical staff are rising to meet patient demand.
• For the nine months ended September 30, 2025, G&A included approximately $1.1 million associated with salaries and wages for additional personnel.
• Management is working to ramp up SO teams, which have an expected 30 to 60-day initial ramp time to become fully functional.

Financing costs are also a component of the cost structure, stemming from the debt taken on to support the strategic pivot. The Interest expense on acquisition-related debt for Q3 2025 is a noted cost, reported at $0.7 million.

The company continues to invest in its core offering, which drives future value but adds to current period costs. This includes Research and development (R&D) for device and protocol improvements, which is an ongoing investment area supporting the proprietary Vivos Method.

Here's a quick look at the key cost components for the three months ended September 30, 2025, compared to the prior year period:

Cost Category	Q3 2025 Amount (in thousands)	Q3 2024 Amount (in thousands)
General and Administrative	7,884	4,487
Cost of Sales	2,846	1,526
Depreciation and Amortization	384	146
Total Operating Expenses	8,711 (Calculated: 7,884 + 403 + 384)	5,000 (Given in context)

Note that Total Operating Expenses in the search result for Q3 2025 is stated as $8.7 million, which is slightly different from the sum of the line items provided in the table ($7,884k + $403k + $384k = $8,671k or $8.671 million). The search result for the nine-month period shows G&A of $19.181 million for Q3 2025.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Revenue Streams

You're looking at Vivos Therapeutics, Inc.'s (VVOS) revenue streams as of late 2025, which clearly show the company's strategic pivot away from its legacy model. The numbers reflect the first full quarter impact of the June 10, 2025, acquisition of The Sleep Center of Nevada (SCN).

The revenue composition is shifting heavily toward direct medical service delivery. Here's the quick math on the new core revenue drivers for the third quarter of 2025:

Revenue Stream Component	Q3 2025 Amount
Diagnostic Sleep Testing Services Revenue (from SCN)	$2.2 million
Treatment Center Revenue (from SCN operations)	$1.3 million
Total Confirmed SCN Service Revenue	$3.5 million

The overall revenue picture for the quarter is built from these new streams, plus product sales, while the old model fades. Total Q3 2025 revenue was reported at $6.8 million, up 78% sequentially over Q2 2025.

The key revenue streams you need to track are:

• Service revenue from sleep testing and treatment centers of $4.6 million in Q3 2025.
• Product revenue from sales of oral appliance arches of $2.2 million in Q3 2025.
• Treatment center revenue from SCN operations of $1.3 million in Q3 2025.
• Diagnostic sleep testing services revenue from SCN of $2.2 million in Q3 2025.

The legacy stream is definitely shrinking, which is by design. Vivos Therapeutics is actively weaning itself off the old way of doing business. The legacy Vivos Integrated Provider (VIP) enrollment fees are decreasing, and management has stated they expect to be finished recognizing any such legacy revenue by the end of 2026. For the nine months ended September 30, 2025, this legacy revenue saw a decrease of approximately $2.6 million compared to the prior year period, showing how quickly the transition is taking hold. Honestly, if onboarding takes longer than expected, churn risk rises, but the stated goal is clear.

Here are the other key financial data points related to revenue for the nine months ended September 30, 2025:

• Nine-month total revenue reached $13.6 million.
• Nine-month revenue represented a 20% increase compared to the same period in 2024.
• Gross margin for Q3 2025 was 58%, down from 60% in Q3 2024.

Finance: draft 13-week cash view by Friday.